Lilly Acquires DACRA Pipeline from KeyBioScience, with Diabetes Treatments in Mind - Genetic Engineering & Biotechnology News

Lilly Acquires DACRA Pipeline from KeyBioScience, with Diabetes Treatments in Mind Genetic Engineering & Biotechnology News Eli Lilly will acquire worldwide rights from KeyBioscience to develop and commercialize its pipeline of Dual Amylin Calcitonin Receptor Agonists (DACRAs) for type 2 diabetes and other metabolic disorders, the companies said today. The companies have ... and more »